ImmunoGen Inc (IMGN)

[skitahoe]

It's nice to see some life here, but for a lot more information on IMGN have a look at Investor's Village.

For those who know me, I've expressed the fact that to be a really successful year, IMGN should close the year at or above where it ended the year in 2015, roughly $13. I believe with the conferences scheduled for later this year we could do that well, or better.

With the partnership with Jazz, IMGN should have eliminated all doubts about their ability to finish development of IMGN853 financially. I don't believe it's ever been their goal to support full commercialization of the drug worldwide, but a ROW partnership either keeping the U.S. or all of North America for themselves will grow dramatically in value as approval is approached. I believe we'll know a lot more from technical conferences before year's end, but the Phase 3 won't see results for a substantial period of time beyond that, unless a decision is made to end it early.

Gary